None
EN
Kelun-Biotech’s SKB-565 cleared to enter clinic in China
[]
BioWorld
Immuno-oncologyKelun-Biotech’s SKB-565 cleared to enter clinic in ChinaSichuan Kelun-Biotech Biopharmaceutical Co. Ltd. said its IND application was approved in China for SKB-565, its dual-payload antibody-drug conjugate (ADC), for the treatment of advanced solid tumors.